MA48730A - Compositions et méthodes de traitement de synucléinopathies - Google Patents

Compositions et méthodes de traitement de synucléinopathies

Info

Publication number
MA48730A
MA48730A MA048730A MA48730A MA48730A MA 48730 A MA48730 A MA 48730A MA 048730 A MA048730 A MA 048730A MA 48730 A MA48730 A MA 48730A MA 48730 A MA48730 A MA 48730A
Authority
MA
Morocco
Prior art keywords
synucleinopathies
compositions
treatment
methods
Prior art date
Application number
MA048730A
Other languages
English (en)
French (fr)
Inventor
Kumar Kandadi Muralidharan
Natasha Penner
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MA48730A publication Critical patent/MA48730A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA048730A 2017-03-31 2018-03-30 Compositions et méthodes de traitement de synucléinopathies MA48730A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479818P 2017-03-31 2017-03-31
US201762528790P 2017-07-05 2017-07-05

Publications (1)

Publication Number Publication Date
MA48730A true MA48730A (fr) 2020-04-08

Family

ID=62092178

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048730A MA48730A (fr) 2017-03-31 2018-03-30 Compositions et méthodes de traitement de synucléinopathies

Country Status (13)

Country Link
US (1) US20200377579A1 (https=)
EP (1) EP3630815A1 (https=)
JP (1) JP2020512368A (https=)
KR (1) KR20200026789A (https=)
CN (1) CN110997715A (https=)
AU (1) AU2018242626A1 (https=)
BR (1) BR112019020335A2 (https=)
CA (1) CA3058304A1 (https=)
IL (1) IL269637A (https=)
JO (1) JOP20190227A1 (https=)
MA (1) MA48730A (https=)
SG (1) SG11201908672WA (https=)
WO (1) WO2018178950A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
JP2021502955A (ja) * 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2020079113A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
CA3159964A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
IL301039A (en) 2020-09-10 2023-05-01 Prothena Biosciences Ltd Treatment of parkinson's disease
KR20240055758A (ko) 2021-09-16 2024-04-29 하. 룬드벡 아크티에셀스카브 시누클레인병증을 치료하기 위한 조성물 및 방법
WO2024167821A2 (en) * 2023-02-06 2024-08-15 Creative Bio-Peptides, Inc. Peptides for treating neurological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU2009328505B2 (en) * 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
HUE041391T2 (hu) * 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн

Also Published As

Publication number Publication date
WO2018178950A1 (en) 2018-10-04
JP2020512368A (ja) 2020-04-23
JOP20190227A1 (ar) 2019-09-30
CN110997715A (zh) 2020-04-10
IL269637A (en) 2019-11-28
US20200377579A1 (en) 2020-12-03
CA3058304A1 (en) 2018-10-04
BR112019020335A2 (pt) 2020-04-28
AU2018242626A1 (en) 2019-10-10
EP3630815A1 (en) 2020-04-08
KR20200026789A (ko) 2020-03-11
SG11201908672WA (en) 2019-10-30

Similar Documents

Publication Publication Date Title
EP3607072A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR PHENYLKETONURIA
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA46102A (fr) Composés de tétracycline et méthodes de traitement
EP3687981A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EP3397149A4 (en) TISSUE CHARTING AND TREATMENT
EP3600285A4 (en) TOPICAL COMPOSITIONS AND METHODS OF TREATMENT
EP3634442A4 (en) METHODS OF TREATMENT AND PREVENTION OF DISEASES
EP3390634A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3302379A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM
EP3442515A4 (en) Liposomal preparation and treatment methods
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
MA52790A (fr) Compositions et méthodes de traitement de la thrombopénie immune
EP3519058C0 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF HAIR
EP3458159A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MITOCHONDRIAL MYOPATHIA
EP3423100A4 (en) COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF
EP3373962A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCER DISEASES
EP3658142A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF GALACTOSEMIA
EP3713583A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF THE SKIN
EP3691649A4 (en) WOUND TREATMENT COMPOSITIONS AND METHODS
EP3313186A4 (en) LPT-723 AND IMMUNE CONTROL POINT COMBINATIONS AND TREATMENT PROCEDURES
EP3298141A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP3386507A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF STOMACH DISEASES
EP3609500A4 (en) ADIPOCYTE TREATMENT